Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera

1. VERIFY study shows rusfertide effectively treats polycythemia vera. 2. More than doubled response rate; improved quality of life. 3. Reduced need for phlebotomy and better hematocrit control. 4. Common adverse event: localized injection-site reactions. 5. Evaluated fatigue using PROMIS Fatigue Short Form, showing significant improvement. 6. Rusfertide may reduce risk of complications from current therapies. 7. Future studies will assess longer-term safety and efficacy.